Radiopharm Reports 93% Concordance for RAD101, Plans Phase 3 Trial

RAD101 Demonstrates High Diagnostic Accuracy for Brain Metastases

Radiopharm Theranostics (ASX:RAD) has cleared a significant clinical milestone with its RAD101 imaging agent, reporting a 93% concordance rate between its Fluorine-18 labelled PET scans and conventional MRI in detecting recurrent brain metastases. This primary endpoint was met across 30 evaluable patients in the Phase 2b trial, underscoring RAD101’s potential to improve diagnostic precision where MRI alone often struggles, particularly in distinguishing tumor recurrence from treatment effects.

Adding weight to these findings, preliminary sensitivity data from 14 patients with six-month follow-up or biopsy confirmation showed an encouraging 86% ability to correctly identify disease presence. Specificity data, crucial for understanding false positive rates, is expected in late 2026. The unmet need is stark: over 300,000 U.S. patients are diagnosed annually with cerebral metastases, yet no PET imaging agent currently holds regulatory approval for this indication.

FDA Fast Track and Siemens Partnership Accelerate Phase 3 Preparation

RAD101 has secured FDA Fast Track designation, a regulatory nod aimed at expediting its development and review. Radiopharm is finalising Phase 3 trial design with the FDA, targeting a pivotal multi-centre study to commence in the U.S. in Q4 2026. The company’s collaboration with Siemens Healthineers to manufacture and distribute the radiolabelled doses provides a critical supply chain backbone ahead of this launch.

This imaging market, estimated to exceed $600 million, is poised for disruption if RAD101 can deliver on its promise to offer a more accurate and reliable diagnostic tool for neuro-oncology clinicians and patients alike. The trial’s focus on fatty acid synthase (FASN) as a novel biomarker differentiates RAD101 from existing imaging modalities, potentially enabling earlier and clearer detection of brain metastases from various solid tumors.

RAD204 Phase 1 Trial Shows Early Therapeutic Promise in Advanced Cancers

Parallel to its diagnostic efforts, Radiopharm’s therapeutic candidate RAD204 is making strides in its ongoing Phase 1 trial targeting PD-L1-positive advanced solid tumors. The first two patients in the highest dose cohort have shown promising outcomes: one achieved a confirmed partial response sustained beyond seven months, while the other exhibited early tumor shrinkage and remains progression-free.

RAD204’s safety profile remains favourable, with no dose-limiting toxicities reported across all cohorts to date. Kidney uptake, often a concern with radiotherapeutics, has been limited, supporting further dose escalation. These data bolster the case for RAD204’s potential as a repeat-dosed radioligand therapy designed to overcome resistance mechanisms in PD-L1-associated malignancies such as lung, breast, and melanoma cancers.

Strategic Positioning and Next Steps

Radiopharm’s dual-track progress; advancing RAD101 toward a registrational Phase 3 trial and demonstrating early efficacy with RAD204; reflects a broad and differentiated pipeline in oncology radiopharmaceuticals. The company’s ability to secure key partnerships and regulatory designations enhances its prospects in competitive and high-value markets.

Investors should watch for the upcoming specificity data for RAD101 expected in Q4 2026, which will complete the diagnostic accuracy profile ahead of the Phase 3 launch. Similarly, further efficacy and safety updates from the RAD204 dose escalation study will be critical to defining its therapeutic window and informing Phase 2 planning.